102 related articles for article (PubMed ID: 31650877)
1. CA 19-9 doubling time in pancreatic cancer as a predictor of venous thromboembolism: a hospital database study.
Peippo MH; Kurki S; Seppänen H; Lassila R; Carpén O
Acta Oncol; 2020 Feb; 59(2):237-241. PubMed ID: 31650877
[No Abstract] [Full Text] [Related]
2. Association between Level of Tumor Markers and Development of VTE in Patients with Pancreatic, Colorectal and Ovarian Ca: Retrospective Case- Control Study in Two Community Hospitals.
Awkar N; Amireh S; Rai S; Shaaban H; Guron G; Maroules M
Pathol Oncol Res; 2018 Apr; 24(2):283-287. PubMed ID: 28470575
[TBL] [Abstract][Full Text] [Related]
3. Potential Biomarkers in Lewis Negative Patients With Pancreatic Cancer.
Luo G; Liu C; Guo M; Cheng H; Lu Y; Jin K; Liu L; Long J; Xu J; Lu R; Ni Q; Yu X
Ann Surg; 2017 Apr; 265(4):800-805. PubMed ID: 28267695
[TBL] [Abstract][Full Text] [Related]
4. The Feasibility of Serum Multiple Tumor Markers Test Between Patients with Primary Pancreatic Cancer and Those with Benign Pancreatic Cystic Disease.
Lee JH
Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625360
[TBL] [Abstract][Full Text] [Related]
5. Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis.
Nishida K; Kaneko T; Yoneda M; Nakagawa S; Ishikawa T; Yamane E; Nishioka B; Miyamoto Y; Takano H; Yoshikawa T; Kondo M
J Surg Oncol; 1999 Jul; 71(3):140-6. PubMed ID: 10404129
[TBL] [Abstract][Full Text] [Related]
6. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
7. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer.
Qi Q; Geng Y; Sun M; Chen H; Wang P; Chen Z
Pancreas; 2015 Aug; 44(6):977-82. PubMed ID: 25931258
[TBL] [Abstract][Full Text] [Related]
8. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
9. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma.
Diaz CL; Cinar P; Hwang J; Ko AH; Tempero MA
Am J Clin Oncol; 2019 Dec; 42(12):898-902. PubMed ID: 31634155
[TBL] [Abstract][Full Text] [Related]
10. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients.
Santucci N; Facy O; Ortega-Deballon P; Lequeu JB; Rat P; Rat P
Pancreatology; 2018 Sep; 18(6):666-670. PubMed ID: 30153902
[TBL] [Abstract][Full Text] [Related]
11. Clinical value and impact on prognosis of peri-operative CA 19-9 serum levels in stage I and II adenocarcinoma of the pancreas.
Piagnerelli R; Marrelli D; Roviello G; Ferrara F; Di Mare G; Voglino C; Petrioli R; Marini M; Macchiarelli R; Roviello F
Tumour Biol; 2016 Feb; 37(2):1959-66. PubMed ID: 26334620
[TBL] [Abstract][Full Text] [Related]
12. Dynamic Behavior of Ca 19-9 and Pancreatic Cancer Recurrence: Enough Data to Drive Salvage Therapy?
Malleo G
Ann Surg Oncol; 2018 Nov; 25(12):3419-3420. PubMed ID: 30128901
[No Abstract] [Full Text] [Related]
13. Proposed cut-off value of CA19-9 for detecting pancreatic cancer in patients with diabetes: a case-control study.
Murakami M; Nagai Y; Tenjin A; Tanaka Y
Endocr J; 2018 Jun; 65(6):639-643. PubMed ID: 29643268
[TBL] [Abstract][Full Text] [Related]
14. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
[TBL] [Abstract][Full Text] [Related]
15. [CA19-9: more than just a biomarker?].
Ammer-Herrmenau C; Neesse A
Z Gastroenterol; 2020 Jan; 58(1):74-75. PubMed ID: 31931544
[No Abstract] [Full Text] [Related]
16. Plasma cathepsin L: a prognostic marker for pancreatic cancer.
Singh N; Das P; Gupta S; Sachdev V; Srivasatava S; Datta Gupta S; Pandey RM; Sahni P; Chauhan SS; Saraya A
World J Gastroenterol; 2014 Dec; 20(46):17532-40. PubMed ID: 25516668
[TBL] [Abstract][Full Text] [Related]
17. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
Medicine (Baltimore); 2018 Jan; 97(4):e9707. PubMed ID: 29369199
[TBL] [Abstract][Full Text] [Related]
18. Re: CA 19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and preoperative therapy.
Bold RJ
Ann Surg Oncol; 2013 Jul; 20(7):2108-10. PubMed ID: 23563959
[No Abstract] [Full Text] [Related]
19. Diagnostic value of K-ras mutations in serum of pancreatic cancer patients.
Theodor L; Melzer E; Sologov M; Bar-Meir S
Ann N Y Acad Sci; 2000 Apr; 906():19-24. PubMed ID: 10818590
[No Abstract] [Full Text] [Related]
20. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
